Sanofi, BEYFORTUS
"We're proud to offer BEYFORTUS doses to help protect every eligible baby in the US this RSV season. This accomplishment aimed at equitable access was made possible through close partnership ...
BEYFORTUS is the first and only long-acting monoclonal antibody approved for the prevention of RSV lower respiratory tract disease (LRTD) in newborns and infants born during or entering their ...
The Nunavut government says it will provide immunization against respiratory syncytial virus to all infants in the territory ...
October: time for muddy soccer practices, cider pressing and Halloweentown ... And time to roll up your sleeves.
RSV infects almost every child before they turn 2, and kills more than 100,000 infants worldwide each year. Machine learning ...
As this year’s respiratory syncytial virus (RSV) season approaches, Beyfortus makers Sanofi and AstraZeneca are making ...